CHX2 Antibody

Overview of CDX2 Antibody

CDX2 is a transcription factor critical in intestinal development and differentiation. The CDX2 Antibody (#3977) from Cell Signaling Technology is a rabbit polyclonal antibody targeting human CDX2 protein . It is validated for:

• Western blotting (WB)

• Immunoprecipitation (IP)

Research Applications

CDX2 Antibody is widely used to study:

• Intestinal epithelial cell differentiation

• Colorectal cancer biomarkers (CDX2 loss correlates with poor prognosis)

• Gastrointestinal development in model organisms

Validation and Quality Control

• Specificity: Recognizes endogenous CDX2 at 38 kDa in WB .

• Batch Consistency: Rigorously validated for minimal lot-to-lot variability .

• Negative Controls: Recommended for confirming signal specificity (e.g., CDX2-knockout cell lines).

Comparative Analysis With Other Antibodies

While CDX2-specific data dominates the results, broader antibody engineering principles from COVID-19 research highlight trends relevant to all therapeutic antibodies:

• Neutralization mechanisms: Epitope binding and steric hindrance (e.g., SARS-CoV-2 neutralizing antibodies )

• Fc modifications: Half-life extension via YTE mutations (M252Y/S254T/T256E)

• Bispecific formats: Dual-targeting strategies for enhanced efficacy

Limitations and Future Directions

• Species Restrictions: Limited to human samples .

• Therapeutic Potential: No current FDA approvals for CDX2-targeted therapies, unlike oncology antibodies (e.g., daratumumab ).